Developer docs
API playgroundTry for free, no card

Search company profiles

Enveda Biosciences

Full company profile

uuid00000kk

Namestring
Enveda Biosciences
Legal namestring
Enveda Therapeutics, Inc.
Websiteurl
enveda.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, natural product therapeutics, plant-derived pharmaceuticals, foundation model chemistry, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
Product category
Drug Discovery & Development (Natural Product-Derived Pharmaceuticals)
Social media profiles3 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharma strategic investment / partnership capital
TypeLicensing Royalties
Description

Strategic equity investments from pharmaceutical partners (e.g., Sanofi's investment in Enveda's Series C, bringing total to $150M) to advance the platform and specific clinical programs to trials. Acts as upfront partnership capital with embedded collaboration rights.

biospace.com
2Venture capital equity funding
TypeSubscription Recurring
Description

Pre-revenue clinical-stage biotech funded primarily through successive equity rounds (Series A led by Lux Capital, B1 led by Kinnevik, C led by Kinnevik/FPV with Sanofi, D led by Premji Invest). Total raised ~$517M. Reaches unicorn status in Sept 2025 at >$1B valuation.

businesswire.com
3Future pharma out-licensing and milestone economics
TypeTransaction Fee
Description

Website contact form explicitly solicits in-licensing and out-licensing inquiries, indicating forward plan to monetize the pipeline of 10+ development candidates via asset-level deals, milestones, and royalties on approved drugs once clinical data validates programs.

enveda.com
Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Enveda Biosciences is a clinical-stage biotechnology company that discovers and develops small-molecule drug candidates derived from natural products, primarily plant sources. The company uses an AI-driven platform that combines mass spectrometry, a proprietary foundation model (PRISM), and the world's largest searchable plant-derived molecule library to identify therapeutic compounds. Its current pipeline includes three clinical-stage assets (ENV-294 for atopic dermatitis and asthma, ENV-308 for obesity, and ENV-6946 for inflammatory bowel disease), six IND-enabling candidates, and 17 development candidates.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1ENV-294 (clinical asset)
CategoryDrug Candidate (Inflammation / Immunology)
2ENV-308 (clinical asset)
CategoryDrug Candidate (Metabolic Disease)
3ENV-6946 (clinical asset)
CategoryDrug Candidate (Inflammation / Immunology)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors37 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enveda Biosciences

Drug Discovery & Development (Natural Product-Derived Pharmaceuticals)enveda.com

Enveda Biosciences firmographics

Firmographics
Name
Enveda Biosciences
Legal name
Enveda Therapeutics, Inc.
Website
https://enveda.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Enveda Biosciences industry classification

Industry
Product category
Drug Discovery & Development (Natural Product-Derived Pharmaceuticals)
NAICS
Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Natural product therapeutics
  • Plant-derived pharmaceuticals
  • Foundation model chemistry
  • Clinical-stage biotechnology

Where Enveda Biosciences is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Enveda Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharma strategic investment / partnership capital: Strategic equity investments from pharmaceutical partners (e.g., Sanofi's investment in Enveda's Series C, bringing total to $150M) to advance the platform and specific clinical programs to trials. Acts as upfront partnership capital with embedded collaboration rights.
  2. Venture capital equity funding: Pre-revenue clinical-stage biotech funded primarily through successive equity rounds (Series A led by Lux Capital, B1 led by Kinnevik, C led by Kinnevik/FPV with Sanofi, D led by Premji Invest). Total raised ~$517M. Reaches unicorn status in Sept 2025 at >$1B valuation.
  3. Future pharma out-licensing and milestone economics: Website contact form explicitly solicits in-licensing and out-licensing inquiries, indicating forward plan to monetize the pipeline of 10+ development candidates via asset-level deals, milestones, and royalties on approved drugs once clinical data validates programs.

Go-to-market motion4 records

Enveda Biosciences product offering

Product offering

Core offering

Enveda Biosciences is a clinical-stage biotechnology company that discovers and develops small-molecule drug candidates derived from natural products, primarily plant sources. The company uses an AI-driven platform that combines mass spectrometry, a proprietary foundation model (PRISM), and the world's largest searchable plant-derived molecule library to identify therapeutic compounds. Its current pipeline includes three clinical-stage assets (ENV-294 for atopic dermatitis and asthma, ENV-308 for obesity, and ENV-6946 for inflammatory bowel disease), six IND-enabling candidates, and 17 development candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • ENV-294 (clinical asset)
  • ENV-308 (clinical asset)
  • ENV-6946 (clinical asset)

Companies that use Enveda Biosciences

Customer profile

Ideal customer profiles2 records

Enveda Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Enveda Biosciences partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Enveda Biosciences competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Enveda Biosciences social profiles

Digital presence

Enveda Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enveda Biosciences leadership team

Management profile

Number of profiles

Profiles18 records

Enveda Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Enveda Biosciences funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors37 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enveda Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enveda Biosciences

What does Enveda Biosciences do?

Enveda Biosciences is a clinical-stage biotechnology company that discovers and develops small-molecule drug candidates derived from natural products, primarily plant sources. The company uses an AI-driven platform that combines mass spectrometry, a proprietary foundation model (PRISM), and the world's largest searchable plant-derived molecule library to identify therapeutic compounds. Its current pipeline includes three clinical-stage assets (ENV-294 for atopic dermatitis and asthma, ENV-308 for obesity, and ENV-6946 for inflammatory bowel disease), six IND-enabling candidates, and 17 development candidates.

Is Enveda Biosciences a public or private company?

Enveda Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Enveda Biosciences founded?

Enveda Biosciences was founded in 2019. It employs 251 to 500 people.

Where is Enveda Biosciences based?

Enveda Biosciences is headquartered in Boulder, United States, in the North America region.

How does Enveda Biosciences make money?

Three revenue lines are on record. Pharma strategic investment / partnership capital is the primary driver. The others are venture capital equity funding and future pharma out-licensing and milestone economics.

Does Enveda Biosciences have an API?

No public API is recorded for Enveda Biosciences.

What industry is Enveda Biosciences in?

Enveda Biosciences's product category is Drug Discovery & Development (Natural Product-Derived Pharmaceuticals). Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaAnthropic's Claude cut Enveda's drug records' review time by 89%Anthropic's Claude helped Enveda cut drug manufacturing record review time by 89%, from 25.9 hours to 2.8 hours. The AI system also generated an FDA application draft in four hours versus three months manually. Both companies said AI could reduce administrative burden but noted results are from specific workflows.Business Wire BlogEnveda Collaborates with Anthropic to Accelerate Drug DevelopmentEnveda announced results from its collaboration with Anthropic to streamline drug development documentation. The CMC Document Processor reduced batch-record review time by 89% and identified all 11 actionable issues, while Claude generated an IND draft in four hours versus three months manually. Both systems supported human oversight without replacing quality processes.Labiotech.euThe biggest biotech funding rounds in September 2026In September 2026, Enveda raised $311 million in private funding, ADARx priced a $446.3 million IPO, and Electra Therapeutics raised $350 million. North American companies led with $1.595 billion in private rounds, while public fundraising totaled $1.2 billion across five rounds.Business Wire BlogEnveda Announces Late-Breaker Oral Presentation of New Mechanistic and Biomarker Data from the Phase 1b Trial of ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic DermatitEnveda announced that new mechanistic and biomarker data from its Phase 1b trial of ENV-294 will be presented at EADV 2026 in Vienna. The oral presentation will cover the drug's role as a Rac2 modulator, with initial Phase 1b results showing durable clinical improvements. The company also plans a separate oral presentation of the Phase 1b results.Longevity.TechnologyNature’s chemistry, read by AI, funded at $311mEnveda closed a $311 million Series E round led by Catalio Capital, bringing total funding to over $845 million. The company's AI-discovered drug ENV-308 is in trials to help maintain weight loss after GLP-1 drugs, showing well-tolerated results in an 88-person study. Funds will advance ENV-294 and ENV-308 into later-stage trials.VC News DailyEnveda Inks $311 Million Series E FundingEnveda closed a $311 million Series E financing led by Catalio Capital Management, with new investment from Durable Capital Partners, ICONIQ, and others. The round follows positive clinical readouts in atopic dermatitis and metabolic health, bringing total capital raised to over $845 million.SwipelineEnveda, yapay zeka destekli ilaç keşfi için 311 milyon dolar yatırım aldıEnveda completed a $311 million Series E round led by Catalio Capital Management, valuing the biotech at $2 billion. The company uses AI to identify drug candidates from natural sources and plans to advance more candidates to clinical trials.Pharmaceutical TechnologyEnveda nabs $311m to progress nature-derived drug pipeline - Pharmaceutical TechnologyEnveda closed a $311M Series E round led by Catalio Capital to advance its AI-discovered therapies for inflammatory and metabolic disorders. The funds will push ENV-294 (Phase II eczema/asthma) and ENV-308 (weight loss) into later-stage trials, with ENV-294 showing 85% disease reduction in a Phase Ib study.citybizEnveda Raises $311M Series E Led by Catalio Capital to Advance Drug PipelineEnveda raised $311 million in a Series E round led by Catalio Capital Management, bringing total funding to over $845 million. The company will use the proceeds to advance three oral medicines through clinical development and expand its pipeline. Its clinical pipeline includes ENV-294 for eczema and asthma, ENV-308 for weight loss, and ENV-6946 for inflammatory bowel disease.Dagens industriKinnevik-innehav dubblar värderingenEnveda, a biotech company, raised $311 million in a Series E round led by Catalio Capital Management. The company is valued at $2 billion, or 19.8 billion Swedish kronor, double its valuation a year earlier.